•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences

Khaitan, CAM, 2 foreigns on record $1.3bn Gland Pharma FDI from China

"Shanghai Fosun Pharmaceutical (Group) Co. Ltd, the Hong Kong-listed company controlled by billionaire Guo Guangchang, will acquire India’s Gland Pharma Ltd for $1.3 billion (Rs 8,700 crore), the company announced on Thursday. According to the agreement, Fosun will acquire an approximate 86% stake in Gland, including the 36% stake held by existing private equity firm KKR & Co,” reported Mint.

Fosun was represented by Khaitan & Co partner Niren Patel, principal associate Vivek Sriram, senior associate Vidur Sinha and associate Niharika Mepani. They were also assisted by associates Pooja Radia and Shriyani Datta on corporate due diligence; associate director Vinita Krishnan senior associate and Raghav Bajaj on direct tax aspects; and counsel Smriti Yadav and associate Jahnvi Shah on intellectual property due diligence.

Fosun drafted in Troutman Sanders LLP (Shanghai) partner Chengfei Ding on non-Indian law aspects of the deal.

Gland Pharma and KKR instructed Cyril Amarchand Mangaldas Bangalore partner Reeba Chacko, and relied on Simpson Thacher & Bartlett (Hong Kong) as foreign counsel with partner Kathryn K Sudol, counsel Ian Ho and partner Shannon M Itoyama.

Value: $1.3bn (Rs 8,700 crore)

Click to show 2 comments
at your own risk
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.